查看文章

Recombinant human erythropoietin treatment improves platelet function in uremic patients. The effect of recombinant human erythropoietin (rHuEPO) on primary hemostasis was tested in 19 hemodialyzed patients. Bleeding time, platelet aggregation and platelet interaction with vessel subendothelium (SE) under flow conditions were determined before treatment and after patients reached hematocrits ≥30%. Two thrombotic events (an acute myocardial infarction and an AV fistula clotting) were recorded during the early stages of treatment. A shortening of average bleeding times (P < 0.01), an increase in platelet count (P < 0.01) and an improvement of platelet aggregation (P < 0.01) and of platelet-SE interaction (P < 0.01) were observed. A low correlation index was found between hematocrit and bleeding time (r = -0.351, P < 0.05). To assess a possible effect of rHuEPO on platelet function, the same parameters …